Want to see HK:6929 full AI Analyst Report?
Top Page
OrbusNeich Medical Group Holdings Limited
(6929)
Select Model
Select Model
Rating:78Outperform
Price Target:
HK$4.50
▲(1.35% Upside)
Action:Reiterated
Date:08/23/26
The score is driven primarily by strong financial positioning (notably an exceptionally low-leverage balance sheet) and an attractive valuation (low P/E and high dividend yield). Offsetting these positives are weakened cash generation and reduced free cash flow in 2024–2025, plus momentum indicators that are strong but approaching overbought levels.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s interventional cardiology and endovascular products. Growth across several years provides a durable base for operating leverage, product adoption and broader international commercialization.
Negative Factors
Weak Cash Conversion
Weak conversion of accounting earnings into operating cash may indicate working-capital or reinvestment pressure. If sustained, it could constrain internally funded growth and reduce the company’s ability to convert strong reported margins into financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s interventional cardiology and endovascular products. Growth across several years provides a durable base for operating leverage, product adoption and broader international commercialization.
Read all positive factors
OrbusNeich Medical Group Holdings Limited (6929) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.16B
Dividend Yield7.01%
Average Volume (3M)98.92K
Price to Earnings (P/E)9.1
Beta (1Y)0.57
Revenue Growth16.25%
EPS Growth7.80%
CountryHK
Employees1,528
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume65,800
30 Day Avg. Volume98,916
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.30Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$207.00M
OrbusNeich Medical Group Holdings Limited Business Overview & Revenue Model
Company Description
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The co...
How the Company Makes Money
null...
OrbusNeich Medical Group Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 195.37M | 180.45M | 164.10M | 153.87M | 136.82M | 116.46M |
| Gross Profit | 134.03M | 122.43M | 114.47M | 106.50M | 92.46M | 81.17M |
| EBITDA | 50.31M | 42.78M | 36.76M | 53.97M | 27.14M | 8.31M |
| Net Income | 43.63M | 41.90M | 39.72M | 45.07M | 18.49M | -4.44M |
Balance Sheet | ||||||
| Total Assets | 459.67M | 452.85M | 431.01M | 410.14M | 351.06M | 268.53M |
| Cash, Cash Equivalents and Short-Term Investments | 199.23M | 218.68M | 248.59M | 256.21M | 247.94M | 175.89M |
| Total Debt | 6.77M | 3.91M | 4.20M | 7.46M | 4.03M | 67.69M |
| Total Liabilities | 40.50M | 38.71M | 36.63M | 40.73M | 28.49M | 85.42M |
| Stockholders Equity | 418.18M | 413.00M | 393.31M | 368.40M | 322.57M | 183.11M |
Cash Flow | ||||||
| Free Cash Flow | 11.91M | 1.15M | 1.84M | 15.55M | 20.10M | 18.36M |
| Operating Cash Flow | 21.28M | 19.53M | 13.11M | 23.03M | 23.43M | 20.50M |
| Investing Cash Flow | -57.24M | 15.90M | 8.65M | -52.31M | -169.32M | -5.22M |
| Financing Cash Flow | -17.51M | -29.35M | -18.96M | 884.00K | 57.44M | 146.31M |
OrbusNeich Medical Group Holdings Limited Technical Analysis
Negative
4.44
Price Trends
3.81
Positive
3.89
Negative
3.79
Positive
Market Momentum
0.02
Positive
47.11
Neutral
5.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6929, the sentiment is Negative. The current price of 4.44 is above the 20-day moving average (MA) of 3.93, above the 50-day MA of 3.81, and above the 200-day MA of 3.79, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.11 is Neutral, neither overbought nor oversold. The STOCH value of 5.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6929.
OrbusNeich Medical Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$7.37B | 10.82 | 20.11% | 3.18% | 12.50% | 44.44% | |
78 Outperform | HK$3.16B | 9.11 | 10.50% | 7.01% | 16.25% | 7.80% | |
69 Neutral | HK$16.94B | 71.62 | 5.84% | 0.49% | ― | ― | |
67 Neutral | HK$1.37B | 28.59 | 1.10% | 6.60% | -1.64% | -68.67% | |
61 Neutral | HK$7.27B | 24.96 | 9.64% | 0.79% | 34.94% | 12.99% | |
60 Neutral | HK$14.77B | 9.32 | 5.64% | 5.41% | 7.47% | -26.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6929
OrbusNeich Medical Group Holdings Limited
3.85
-0.52
-11.80%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.23
-2.28
-41.39%
HK:1358
PW Medtech Group Ltd.
0.97
-0.46
-32.12%
HK:3600
Modern Dental Group Limited
7.78
2.57
49.32%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
33.06
0.42
1.28%
HK:6699
Angelalign Technology Inc.
96.85
30.53
46.05%
OrbusNeich Medical Group Holdings Limited Corporate Events
OrbusNeich Names Denise Lau Co-CEO, Tightening Control at the Top
Aug 17, 2026
OrbusNeich Medical Group has appointed executive director Kwai Ching Denise Lau as Co-Chief Executive Officer alongside Chairman David Chien, effective August 17, 2026, while she steps down as Chief Operating Officer. The move elevates a long-serv...
OrbusNeich Declares Interim Dividend for 2026 Financial Year
Aug 14, 2026
OrbusNeich Medical Group Holdings Limited has declared an interim ordinary cash dividend of HKD 0.08 per share for the financial year ending 31 December 2026, based on the reporting period to 30 June 2026. The announcement signals the company̵...
OrbusNeich Delivers Double-Digit Revenue Growth and Higher Margins in First-Half 2026
Aug 13, 2026
OrbusNeich Medical Group Holdings reported solid interim results for the six months ended June 30, 2026, with revenue rising 18.1% year on year to US$98.7 million and gross profit increasing 21.0% to US$67.7 million. Profit attributable to shareho...
OrbusNeich Declares Interim Dividend of HK$0.08 Per Share
Aug 13, 2026
OrbusNeich Medical Group Holdings Limited has declared an interim ordinary dividend of HK$0.08 per share for the six months ended 30 June 2026, underscoring its ability to return cash to shareholders from its medical device operations. The ex-divi...
OrbusNeich Sets August Board Meeting to Review Interim Results and Dividend
Jul 31, 2026
OrbusNeich Medical Group Holdings Limited has scheduled a board meeting for August 13, 2026 to review and approve its interim financial results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider...
OrbusNeich Launches Pivotal Japan Trial for Coronary Drug-Coated Balloon
Jul 22, 2026
OrbusNeich Medical Group Holdings Limited has enrolled the first patient in a pivotal Japanese clinical trial evaluating its proprietary coronary paclitaxel drug-coated balloon, marking a key milestone in its strategy to strengthen its foothold in...
OrbusNeich Shareholders Approve All AGM Resolutions and Final Dividend
Jun 8, 2026
OrbusNeich Medical Group Holdings Limited reported that all resolutions at its annual general meeting on 8 June 2026 were approved by shareholders via poll. The votes confirmed adoption of the 2025 audited financial statements, re-election and app...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.